BioSpace News Archive

Qpex Biopharma, Inc. today announced the exercise of a $10 million option from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to support the advancement of the company’s antibiotic clinical development program.

Disc Medicine, Inc. announced today that company management will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 6th at 1:00 pm ET.

Sanofi announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities..

On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the “Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases” at the 2024 Global Rare Disease Research Symposium and the 2nd China Rare Disease Research and Translational Medicine Conference.

Adela, Inc will present results demonstrating the ability of its tissue-agnostic MRD assay to predict recurrence in head & neck cancer, during an Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2024.

Soterios Pharma announced positive topline results from its randomised, placebo-controlled, multi-dose Phase II trial evaluating STS-01 as a treatment for mild / moderate AA.

Cyclo Therapeutics, Inc. today announced the last patient has been enrolled in the Company’s pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1 (NPC1).

Sarah Cannon Research Institute announced that it will highlight its latest research insights through more than 145 presentations at the 2024 American Society of Clinical Oncology Annual Meeting from Friday, May 31 – Tuesday, June 4 in Chicago, Ill.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) is pleased to announce that further to its news release dated May 16, 2024, the Company has closed the first tranche of its non-brokered private placement (the “Private Placement”) for gross proceeds of $115,000 through the sale of 4,600,000 units of the Company (“Units”) at a price of $0.025 per Unit.

Novavax, Inc. today announced it will participate in the 2024 Jefferies Global Healthcare Conference.